ClinicalTrials.gg
Active, not recruitingNCT04793958Updated Sep 28, 2026

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

A Phase 3 interventional study of MRTX849 and Cetuximab in Advanced Colorectal Cancer and Metastatic Colorectal Cancer, sponsored by Mirati Therapeutics Inc.. Active, not recruiting at 419 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Updated Sep 28, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · Bristol-Myers Squibb.

Enrollment
5th of 27
461 · median 171
Started
2021
the only one that year
Phase 3
3 of 29
none open now
Registered
18th of 29
by date

Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 3 in phase 3, and was the 18th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

03

Conditions studied

  • Advanced Colorectal Cancer
  • Metastatic Colorectal Cancer

Keywords

  • Colorectal Cancer
  • Colorectal Cancer Trial
  • Colorectal Carcinoma
  • Rectal Cancer
  • Colon Cancer
  • KRAS
  • KRAS G12C
  • RAS
  • Colorectal Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
  • Prior receipt of treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
  • Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
  • Active
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    MRTX849 + Cetuximab

    Drug: MRTX849 · Biological: Cetuximab

  • Active comparator
    mFOLFOX6 or FOLFIRI

    Drug: mFOLFOX6 Regimen · Drug: FOLFIRI Regimen

Interventions

  • 28 Day Cycle

  • BiologicalCetuximab

    28 Day Cycle

    Also known as: Erbitux

  • DrugmFOLFOX6 Regimen

    * Fluorouracil * Oxaliplatin * Folinic acid

  • DrugFOLFIRI Regimen

    * Fluorouracil * Irinotecan * Folinic acid

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Defined as time from date of randomization to date of death due to any cause.

    Time frame: 30 months

  2. Progression-free Survival (PFS)

    Defined as time from randomization until disease progression or death from any cause, whichever occurs first.

    Time frame: 30 months

Secondary outcomes

  1. Adverse Events

    Defined as number of patients with treatment emergent AEs.

    Time frame: 30 months

  2. Objective Response Rate (ORR)

    Defined as the percent of patients documented to have a confirmed CR or PR.

    Time frame: 30 months

  3. Duration of Response (DOR)

    Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.

    Time frame: 30 months

  4. Patient Reported Outcomes (PROs)

    To be assessed by European Quality of Life Questionnaire for Cancer Patients (QLQ-C30).

    Time frame: 30 months

  5. Quality of Life Assessment

    To be assessed by European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L).

    Time frame: 30 months

07

Study locations

419 sites
  • Local Institution - 010-855-E
    Alabaster, Alabama 35007, United States
  • Local Institution - 010-855-B
    Bessemer, Alabama 35022, United States
  • Local Institution - 010-855-D
    Birmingham, Alabama 35209, United States
  • Local Institution - 010-855-A
    Birmingham, Alabama 35211, United States
  • Local Institution - 010-855-F
    Birmingham, Alabama 35235, United States
  • Local Institution - 010-855-C
    Birmingham, Alabama 35243, United States
  • Local Institution - 010-855
    Birmingham, Alabama 35243, United States
  • Local Institution - 010-996
    Gilbert, Arizona 85234, United States
  • Local Institution - 010-566
    Goodyear, Arizona 85338, United States
  • Local Institution - 010-989
    Phoenix, Arizona 85054, United States
  • Local Institution - 010-978
    Springdale, Arkansas 72762, United States
  • Local Institution - 010-573
    Bakersfield, California 93309, United States
  • Local Institution - 010-979C
    Chula Vista, California 91911, United States
  • Local Institution - 010-980
    Fresno, California 93701, United States
  • Local Institution - 010-851
    Fullerton, California 92835, United States
  • Local Institution - 010-979A
    La Mesa, California 91942, United States
  • Local Institution - 010-958A
    Los Angeles, California 90033, United States
  • Local Institution - 010-958
    Los Angeles, California 90033, United States
  • Local Institution - 010-551
    Los Angeles, California 90048, United States
  • Local Institution - 010-847
    Newport Beach, California 92663, United States
  • Local Institution - 010-563
    Redlands, California 92373, United States
  • Local Institution - 010-979B
    San Diego, California 92123, United States
  • Local Institution - 010-979D
    San Diego, California 92123, United States
  • Local Institution - 010-979
    San Diego, California 92123, United States
  • Local Institution - 010-982
    San Francisco, California 94115, United States
  • Local Institution - 010-561
    Santa Monica, California 90404, United States
  • Local Institution - 010-571
    Sylmar, California 91342, United States
  • Local Institution - 010-574
    Torrance, California 90505, United States
  • Local Institution - 010-570
    Whittier, California 90602, United States
  • Local Institution - 010-872-H
    Aurora, Colorado 80012, United States
  • Local Institution - 010-810
    Aurora, Colorado 80045, United States
  • Local Institution - 010-872-A
    Boulder, Colorado 80303, United States
  • Local Institution - 010-872-E
    Centennial, Colorado 80112, United States
  • Local Institution - 010-872-C
    Colorado Springs, Colorado 80907, United States
  • Local Institution - 010-872
    Denver, Colorado 80218, United States
  • Local Institution - 010-872-B
    Denver, Colorado 80220, United States
  • Local Institution - 010-872-J
    Lakewood, Colorado 80228, United States
  • Local Institution - 010-872-F
    Littleton, Colorado 80218, United States
  • Local Institution - 010-872-G
    Longmont, Colorado 80501, United States
  • Local Institution - 010-872-I
    Pueblo, Colorado 81008, United States
  • Local Institution - 010-872-D
    Thornton, Colorado 80260, United States
  • Local Institution - 010-949
    Norwich, Connecticut 06360, United States
  • Local Institution - 010-922-A
    Bonita Springs, Florida 34135, United States
  • Local Institution - 010-922-D
    Bradenton, Florida 34211, United States
  • Local Institution - 010-922-E
    Cape Coral, Florida 33909, United States
  • Local Institution - 010-922
    Fort Myers, Florida 33901, United States
  • Local Institution - 010-922-B
    Fort Myers, Florida 33905, United States
  • Local Institution - 010-922-C
    Fort Myers, Florida 33908, United States
  • Local Institution - 010-984-B
    Holiday, Florida 34691, United States
  • Local Institution - 010-829
    Jacksonville, Florida 32224, United States
  • Local Institution - 010-923-A
    Largo, Florida 33770, United States
  • Local Institution - 010-923-B
    Largo, Florida 33770, United States
  • Local Institution - 010-923-C
    Largo, Florida 33770, United States
  • Local Institution - 010-923-D
    Largo, Florida 33770, United States
  • Local Institution - 010-923-E
    Largo, Florida 33770, United States
  • Local Institution - 010-923-F
    Largo, Florida 33770, United States
  • Local Institution - 010-923-G
    Largo, Florida 33770, United States
  • Local Institution - 010-923-H
    Largo, Florida 33770, United States
  • Local Institution - 010-923-I
    Largo, Florida 33770, United States
  • Local Institution - 010-923-J
    Largo, Florida 33770, United States
  • Local Institution - 010-923-K
    Largo, Florida 33770, United States
  • Local Institution - 010-923-L
    Largo, Florida 33770, United States
  • Local Institution - 010-923-M
    Largo, Florida 33770, United States
  • Local Institution - 010-923-N
    Largo, Florida 33770, United States
  • Local Institution - 010-923-O
    Largo, Florida 33770, United States
  • Local Institution - 010-923-P
    Largo, Florida 33770, United States
  • Local Institution - 010-990
    Miami, Florida 33136, United States
  • Local Institution - 010-922-F
    Naples, Florida 34102, United States
  • Local Institution - 010-922-G
    Naples, Florida 34102, United States
  • Local Institution - 010-538
    Ocala, Florida 34474, United States
  • Local Institution - 010-896
    Orlando, Florida 32804, United States
  • Local Institution - 010-988
    Orlando, Florida 32806, United States
  • Local Institution - 010-922-H
    Port Charlotte, Florida 33980, United States
  • Local Institution - 010-923
    St. Petersburg, Florida 33705, United States
  • Local Institution - 010-984
    St. Petersburg, Florida 33709-2236, United States
  • Local Institution - 010-924
    Tallahassee, Florida 32308, United States
  • Local Institution - 010-984-A
    Trinity, Florida 34655, United States
  • Local Institution - 010-926
    West Palm Beach, Florida 33401, United States
  • Local Institution - 010-537
    Weston, Florida 33331, United States
  • Local Institution - 010-956
    Atlanta, Georgia 30322, United States
  • Local Institution - 010-986
    Newnan, Georgia 30265, United States
  • Local Institution - 010-963
    Naperville, Illinois 60540, United States
  • Local Institution - 010-994
    Zion, Illinois 60099, United States
  • Local Institution - 010-569-A
    Indianapolis, Indiana 46237-8601, United States
  • Local Institution - 010-569
    Indianapolis, Indiana 46237-8601, United States
  • Local Institution - 010-991
    Iowa City, Iowa 52242, United States
  • Local Institution - 010-920
    Baton Rouge, Louisiana 70809, United States
  • Local Institution - 010-534
    Baltimore, Maryland 21201, United States
  • Local Institution - 010-997
    Boston, Massachusetts 02215, United States
  • Local Institution - 010-531A
    Brownstown, Michigan 48183, United States
  • Local Institution - 010-531C
    Dearborn, Michigan 48126, United States
  • Local Institution - 010-531
    Detroit, Michigan 48202, United States
  • Local Institution - 010-531B
    Novi, Michigan 48377, United States
  • Local Institution - 010-875
    Minneapolis, Minnesota 55404, United States
  • Local Institution - 010-830
    Rochester, Minnesota 55905, United States
  • Local Institution - 010-838
    Saint Louis Park, Minnesota 55416, United States
  • Local Institution - 010-838A
    Saint Louis Park, Minnesota 55426, United States
  • Local Institution - 010-838B
    Saint Louis Park, Minnesota 55426, United States
  • Local Institution - 010-838C
    Saint Louis Park, Minnesota 55426, United States
  • Local Institution - 010-838D
    Saint Louis Park, Minnesota 55426, United States

Showing the first 100 of 419 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Jan 3;23(1):e247067. doi: 10.6004/jnccn.2024.7067. PubMed 39752885 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jan 2026, 54 months.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 54 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2021
First posted
Mar 11, 2021
StartActual
Jun 24, 2021
Primary completionActual
Jan 16, 2026
CompletionEst.
Oct 23, 2026was Jul 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jul 31, 2026→Oct 23, 2026
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Study completion Jul 31, 2026→Oct 23, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04793958
Responsible party
Sponsor
First posted
Mar 11, 2021
Start date
Jun 24, 2021
Primary completion
Jan 16, 2026
Completion
Oct 23, 2026 (estimated)
Last update
Sep 28, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adagrasib

Start the discussion